AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 41 min read$SMMT

Soni Manmeet Singh purchased $722K of SMMT

Soni Manmeet Singh (COO and CFO) purchased 50,000 shares of Summit Therapeutics Inc. (SMMT) at an average of $14.44 ($14.43–$14.46, $0.72M total) across 2 trades on 2026-06-04.

Original reporting
SEC EDGAR · Soni Manmeet Singh
Published Jun 4, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SMMTBullishMed
01

Why it matters

The transaction adds to insider ownership, potentially influencing investor perception and short‑term price action.

02

Market read

First‑report insider purchase may prompt modest buying interest in SMMT.

03

What to watch

The purchase size relative to market cap is modest; market may already price in insider confidence.

Relevance 6/10Novelty 5/10Timing: same-day filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

COO/CFO Soni Manmeet Singh bought 50,000 shares for $722,250, increasing his stake to over 3.1 million shares.

Expected impact

likely upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is sizable for a micro‑cap and comes from a senior executive, which traders often view as a bullish signal.

Market effects

Sector

May signal confidence in Summit Therapeutics' pipeline, modestly supporting biotech peers.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Low global relevance; impact confined to the stock and its immediate peers.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • company
    Summit Therapeutics Inc.

    Biopharmaceutical company developing therapies for rare diseases.

  • person
    Soni Manmeet Singh

    Chief Operating Officer and Chief Financial Officer of Summit Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SMMT insider trading history →

Related articles

OCT 2
$AZNHighAI 9/10

AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up

AstraZeneca (AZN) will invest $2 billion in Summit Therapeutics (SMMT) for a cancer drug partnership. The investment buys preferred shares convertible at $18.36, a premium to Summit's closing price. The companies will jointly trial Summit's ivonescimab with AstraZeneca's sonesitatug vedotin. AstraZeneca's investment is less than 1% of its market value, while Summit's shares are down year-over-year.

finance.yahoo.com2 min
OCT 1
$SMMTHighAI 9/10

What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?

Summit Therapeutics (SMMT) announced a $2 billion equity and collaboration agreement with AstraZeneca to advance cancer drug ivonescimab. The partnership includes clinical trials for ivonescimab in combination with AstraZeneca's oncology treatments. Summit stated the investment will fund ivonescimab's clinical programs. AstraZeneca's commitment is a major development for Summit, which has no revenue and high R&D spending.

finance.yahoo.com2 min
SEP 30
$SMMTHighAI 9/10

Summit Therapeutics Stock Climbs Wednesday: What's Happening?

Summit Therapeutics (SMMT) shares rose 5.74% to $17.32 on Wednesday after AstraZeneca agreed to invest $2 billion in convertible preferred shares, implying a $18.36 common stock price. The deal funds clinical trials for ivonescimab, a potential cancer treatment, and includes a collaboration to study its combination with AstraZeneca's Sone-Ve. The investment is expected to close within a week, subject to regulatory approvals.

benzinga.com2 min
SEP 30
$AZNHighAI 8/10

AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

AstraZeneca (AZN) will invest $2B in Summit Therapeutics (SMMT) via preferred stock convertible at $18.36/share, a 18.6% premium to Summit's prior close. Summit shares rose 5.88% on the news. The deal includes a trial collaboration but no licensing rights. Summit has no revenue, and its value hinges on ivonescimab, its sole drug. Citi raised its target to $43, citing validation of ivonescimab. The FDA decision on ivonescimab is due by November 2026.

247wallst.com3 min
SEP 30
$SMMTHighAI 9/10

H.C. Wainwright reiterates Summit Therapeutics stock rating as Neutral

H.C. Wainwright reiterated a Neutral rating on Summit Therapeutics (NASDAQ: SMMT) after a $2 billion investment from AstraZeneca. The deal includes a 10% premium on the stock price and shared development costs for gastrointestinal cancer treatments. Summit's stock is trading at $16.39, down 36% in a week, with a market cap of $12.35 billion. Analysts have mixed ratings and price targets, ranging from $30 to $41.

investing.com2 min
SEP 30
$SMMTHighAI 8/10

Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal

Citizens reiterated a Market Outperform rating and $40.00 price target for Summit Therapeutics (NASDAQ:SMMT), citing a $2B AstraZeneca investment and clinical collaborations. The deal funds Summit's clinical and commercial efforts, with Phase 3 trial results expected in 2026-2027. Summit's proforma cash position is $2.8B, and its current ratio is 6.96. Multiple analysts maintain positive ratings and price targets.

investing.com2 min